Biotech Firm ai3Bio Launched with $48 Million
Massachusetts-based ai3Bio emerged from stealth to develop new therapies targeting Th17-expressing T cells.
Live Poll
Do you trust that new medical technologies will effectively manage autoimmune conditions for patients?